Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph not_applicable

40%

Ph phase_1

20%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

N/ANon-phased studies

2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (25.0%)

Phase 41 (25.0%)

N/A2 (50.0%)

Trials by Status

completed360%

recruiting120%

terminated120%

Recent Activity

1 active trials

Showing 5 of 5

completed

Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes

NCT05616273

completednot_applicable

Metabolites Profiling Reveals Nutrient Processing Patterns Upon Dietary Loading

NCT05784506

recruitingphase_4

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

NCT06003153

terminatednot_applicable

Energy Balance Following Islet Transplantation

NCT03063229

completedphase_1

Neulasta in Type 1 Diabetes

NCT00662519

Clinical Trials (5)

Showing 5 of 5 trials

NCT05616273

Stimulated Glucagon as a Biomarker of Hypoglycemic Risk in Type 1 Diabetes

Completed

NCT05784506Not Applicable

Metabolites Profiling Reveals Nutrient Processing Patterns Upon Dietary Loading

Completed

NCT06003153Phase 4

GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH

Recruiting

NCT03063229Not Applicable

Energy Balance Following Islet Transplantation

Terminated

NCT00662519Phase 1

Neulasta in Type 1 Diabetes

Completed

All 5 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 5